Dublin, Ireland, January 24th, 2016 — Nuritas, a biotech start-up using artificial intelligence to revolutionise therapeutics discovery, announced today the appointment of former Novartis Division Head, Dr George Gunn, as Chairman of the company’s Board of Directors.
Dr Gunn brings huge experience and connectivity to the position having been a member of the Novartis Global Executive Committee and Head of the Novartis Animal Health Division from 2004 until early 2015. He also served as Division Head for Novartis Consumer Health from 2008 to 2011 and was the Head of Corporate Social Responsibility for Novartis from 2011 to 2014.
Prior to Novartis, Dr Gunn practiced veterinary medicine for nine years before working at Johnson and Johnson and Pharmacia in an array of increasingly senior executive healthcare roles. George is recognised globally for his leadership and successful impact across a wide platform of healthcare arenas.
Emmet Browne, CEO of Nuritas, said, “As our opportunity is great so are the decisions that lie before us as we scale up. George’s depth of experience, knowledge and wisdom, gained at the highest levels of healthcare leadership, will be a huge addition to us as we deliver on the huge potential that lies within Nuritas. I am delighted to welcome George on board and we all look forward to working with him in the exciting years ahead.
Nuritas also announced today that it had filled two key positions on its Advisory Board in the vital areas of strategic translational science and food/product regulation.
The first of these appointments is Dr Dominique Bridon who has over 25 years of experience in therapeutic discovery, translational research and formulation. More precisely Dominique is an expert in peptide development and commercialisation which is at the core of Nuritas. He has had various roles such as Head of Research and Development in multinational pharmaceutical companies working with Ipsen and Pharmacia as well as being a co-founder of a biotech start-up.
An expert in regulatory affairs in the EU, Steve Morrison has also been added to the Advisory Board and brings over 20 years of regulatory experience in both the pharma and food areas. He is currently the Managing Director of P2F (Pharma to Food) Ventures Limited and was formerly the Chief Operating Officer of Provexis which was the first European Company to achieve an Article 13.5 EFSA health claim.
Founder and Chief Scientific Officer, Dr Nora Khaldi stated,“I am delighted George, Dominique and Steve are joining us. From our first meetings it was clear that all three shared our passion for delivering life-changing ingredients. We are continuing to build a world-class team to help us realise our vision of Nuritas ingredients reaching 1 billion people by 2020.”
For more information, please contact:
Operations & Communications Executive, Nuritas
+ 353 1 430 1290
Nuritas is revolutionising the discovery of novel, natural and scientifically proven active ingredients that promote and manage human health.
The company’s disruptive computational approach to discovery uses artificial intelligence and DNA analysis to, for the first time ever, rapidly and efficiently provide access to the most health-benefiting components within food called peptides. Nuritas’s patented life-changing peptides provide unique solutions for the maintenance of health and wellness. These benefits include: anti-inflammatory activity, antimicrobial activity, muscle recovery enhancement, skin anti-ageing solutions, and the potential management of blood sugar levels for type 2 diabetics.
Nuritas’s dynamic peptides have a vast range of applications in multiple industries including functional and medical foods, pharmaceuticals, dietary supplements, and cosmetics/personal care.
The company has received global recognition for the impact its innovative technology will have on the future of food. This includes winning the overall Innovation Award at the Forbes Reinventing America Summit in 2015, placing them ahead of many US companies. This highly selective competition run by Forbes magazine aimed to identify the company most likely to solve the food and wellness challenges of the 21st century. Edito-in-Chief, Steve Forbes, said at the award ceremony in Salinas, California “we are enthusiastic about this company’s technology and are excited to watch its progress”.
The Irish government also chose Nuritas as the sole representative of national innovation for the 2015 EU Summit. In turn, the EU Commission further recognised the company for its revolutionary work by selecting it as one of Europe’s top 10 most Innovative companies, inviting Nuritas to present a TEDx talk at The Hague to showcase groundbreaking European Innovation.